Search

Your search keyword '"Sung Pei-Hsun"' showing total 530 results
Start Over Author "Sung Pei-Hsun"
530 results on '"Sung Pei-Hsun"'

10. Long term outcomes of intra-carotid arterial transfusion of circulatory derived autologous CD34+ cells for acute ischemic stroke patients—A randomized, open-label, controlled phase II clinical trial

Author

Lin, Hung-Sheng, primary, Sung, Pei-Hsun, additional, Huang, Shu-Hua, additional, Lin, Wei-Che, additional, Chiang, John Y., additional, Ma, Ming-Chun, additional, Chen, Yi-Ling, additional, Chen, Kuan-Hung, additional, Lee, Fan-Yen, additional, Ko, Sheung-Fat, additional, and Yip, Hon-Kan, additional

Published
2024
Full Text
View/download PDF

37. Early and Dose-Dependent Xenogeneic Mesenchymal Stem Cell Therapy Improved Outcomes in Acute Respiratory Distress Syndrome Rodent Through Ameliorating Inflammation, Oxidative Stress, and Immune Reaction

Author

Lin, Kun-Chen, primary, Fang, Wen-Feng, additional, Sung, Pei-Hsun, additional, Huang, Kuo-Tung, additional, Chiang, John Y., additional, Chen, Yi-Ling, additional, Huang, Chi-Ruei, additional, Li, Yi-Chen, additional, Lee, Mel S., additional, and Yip, Hon-Kan, additional

Published
2023
Full Text
View/download PDF

38. Prion Protein Overexpression in Adipose-Derived Mesenchymal Stem Cells (ADMSCs) Effectively Protected Rodent Kidney Against Ischemia-Reperfusion Injury Via Enhancing ATP/Mitochondrial Biogenesis—Role of ADMSC Rejuvenation and Proliferation

Author

Chen, Yen-Ta, primary, Yang, Chih-Chao, additional, Chiang, John Y., additional, Sung, Pei-Hsun, additional, Shao, Pei-Lin, additional, Huang, Chi-Ruei, additional, Lee, Mel S., additional, and Yip, Hon-Kan, additional

Published
2023
Full Text
View/download PDF

39. Combined therapy with shock wave and autologous bone marrow-derived mesenchymal stem cells alleviates left ventricular dysfunction and remodeling through inhibiting inflammatory stimuli, oxidative stress & enhancing angiogenesis in a swine myocardial infarction model

Author

Sheu, Jiunn-Jye, Lee, Fan-Yen, Yuen, Chun-Man, Chen, Yi-Ling, Huang, Tien-Hung, Chua, Sarah, Chen, Yung-Lung, Chen, Chih-Hung, Chai, Han-Tan, Sung, Pei-Hsun, Chang, Hsueh-Wen, Sun, Cheuk-Kwan, and Yip, Hon-Kan

Published
2015
Full Text
View/download PDF

40. Oxidized-LDL Deteriorated the Renal Residual Function and Parenchyma in CKD Rat through Upregulating Epithelial Mesenchymal Transition and Extracellular Matrix-Mediated Tubulointerstitial Fibrosis—Pharmacomodulation of Rosuvastatin

Author

Sung, Pei-Hsun, primary, Cheng, Ben-Chung, additional, Hsu, Tsuen-Wei, additional, Chiang, John Y, additional, Chiang, Hsin-Ju, additional, Chen, Yi-Ling, additional, Yang, Chih-Chao, additional, and Yip, Hon-Kan, additional

Published
2022
Full Text
View/download PDF

45. Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock

Author

Chen, Yu-Wen, Lee, Wei-Chieh, Wu, Po-Jui, Fang, Hsiu-Yu, Fang, Yen-Nan, Chen, Huang-Chung, Tong, Meng-Shen, Sung, Pei-Hsun, Lee, Chieh-Ho, and Chung, Wen-Jung

Subjects
Cardiology and Cardiovascular Medicine
Abstract

BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest. It is difficult to perform VA-ECMO weaning, which may cause circulatory failure and death. Levosimendan is an effective inotropic agent used to maintain cardiac output, has a long-lasting effect, and may have the potential benefit for VA-ECMO weaning. The study aimed to explore the relationship between the early use of levosimendan and the rate of VA-ECMO weaning failure in patients on VA-ECMO support for circulatory failure.MethodsAll patients who underwent VA-ECMO in our hospital for CS between January 2017 and December 2020 were recruited in this cohort study and divided into two groups: without and with levosimendan use. Levosimendan was used as an add-on to other inotropic agents as early as possible after VA-ECMO setting. The primary endpoint was VA-ECMO weaning success, which was defined as survival without events for 24 h after VA-ECMO withdrawl. The secondary outcomes were cardiovascular and all-cause mortality at the 30-day and 180-day follow-up periods post-VA-ECMO initialization.ResultsA total of 159 patients were recruited for our study; 113 patients were enrolled in the without levosimendan-use group and 46 patients were enrolled in the levosimendan-use group. In levosimendan-use group, the patients received levosimendan infusion within 24 h after VA-ECMO initialization. Similar hemodynamic parameters were noted between the two groups. Poorer left ventricular ejection fraction and a higher prevalence of intra-aortic balloon pumping were observed in the levosimendan group. An improved weaning rate (without vs. with: 48.7 vs. 82.6%; p < 0.001), lower in-hospital mortality rate (without vs. with: 68.1 vs. 43.5%; p = 0.007), and 180-day cardiovascular mortality (without vs. with: 75.3 vs. 43.2%; p < 0.001) were also noted. Patients administered with levosimendan also presented a lower rate of 30-day (without vs. with: 75.3 vs. 41.3%; p = 0.034) and 180-day (without vs. with: 77.0 vs. 43.2%; p < 0.001) all-cause mortality.ConclusionEarly levosimendan administration may contribute to increasing the success rate of VA-ECMO weaning and may help to decrease CV and all-cause mortality.

Published
2022

49. Jagged/Notch proteins promote endothelial‐mesenchymal transition‐mediated pulmonary arterial hypertension via upregulation of the expression of GATAs.

Author

Lin, Kun‐Chen, Yeh, Jui‐Ning, Shao, Pei‐Lin, Chiang, John Y., Sung, Pei‐Hsun, Huang, Chi‐Ruei, Chen, Yi‐Ling, Yip, Hon‐Kan, and Guo, Jun

Subjects
PULMONARY arterial hypertension, NOTCH proteins, FIBRONECTINS, PROTEIN expression, SUBCUTANEOUS injections, OXYGEN saturation, MONOCARBOXYLATE transporters, BONE morphogenetic protein receptors
Abstract

This study tested the hypothesis that Jagged2/Notches promoted the endothelial‐mesenchymal transition (endMT)‐mediated pulmonary arterial hypertension (PAH) (i.e. induction by monocrotaline [MCT]/63 mg/kg/subcutaneous injection) through increasing the expression of GATA‐binding factors which were inhibited by propylthiouracil (PTU) (i.e. 0.1% in water for daily drinking since Day 5 after PAH induction) in rodent. As compared with the control (i.e. HUVECs), the protein expressions of GATAs (3/4/6) and endMT markers (Snail/Zeb1/N‐cadherin/vimentin/fibronectin/α‐SMA/p‐Smad2) were significantly reduced, whereas the endothelial‐phenotype markers (CD31/E‐cadherin) were significantly increased in silenced JAG2 gene or in silenced GATA3 gene of HUVECs (all p < 0.001). As compared with the control, the protein expressions of intercellular signallings (GATAs [3/4/6], Jagged1/2, notch1/2 and Snail/Zeb1/N‐cadherin/vimentin/fibronectin/α‐SMA/p‐Smad2) were significantly upregulated in TGF‐ß/monocrotaline‐treated HUVECs that were significantly reversed by PTU treatment (all p < 0.001). By Day 42, the results of animal study demonstrated that the right‐ventricular systolic‐blood‐pressure (RVSBP), RV weight (RVW) and lung injury/fibrotic scores were significantly increased in MCT group than sham‐control (SC) that were reversed in MCT + PTU groups, whereas arterial oxygen saturation (%) and vasorelaxation/nitric oxide production of PA exhibited an opposite pattern of RVW among the groups (all p < 0.0001). The protein expressions of hypertrophic (ß‐MHC)/pressure‐overload (BNP)/oxidative‐stress (NOX‐1/NOX‐2) biomarkers in RV and the protein expressions of intercellular signalling (GATAs3/4/6, Jagged1/2, notch1/2) and endMT markers (Snail/Zeb1/N‐cadherin/vimentin/fibronectin/TGF‐ß/α‐SMA/p‐Smad2) in lung parenchyma displayed an identical pattern of RVW among the groups (all p < 0.0001). Jagged‐Notch‐GATAs signalling, endMT markers and RVSBP that were increased in PAH were suppressed by PTU. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Adipose‐derived mesenchymal stem cells overexpressing prion improve outcomes via the NLRP3 inflammasome/DAMP signalling after spinal cord injury in rat.

Author

Yin, Tsung‐Cheng, Li, Yi‐Chen, Sung, Pei‐Hsun, Chiang, John Y., Shao, Pei‐Lin, Yip, Hon‐Kan, and Lee, Mel S.

Subjects
SPINAL cord injuries, NLRP3 protein, INFLAMMASOMES, GENETIC overexpression, MESENCHYMAL stem cells, SCRAPIE, PRIONS, PROTEIN expression
Abstract

Traumatic spinal cord injury (SCI) is a highly destructive disease in human neurological functions. Adipose‐derived mesenchymal stem cells (ADMSCs) have tissue regenerations and anti‐inflammations, especially with prion protein overexpression (PrPcOE). Therefore, this study tested whether PrPcOE‐ADMSCs therapy offered benefits in improving outcomes via regulating nod‐like‐receptor‐protein‐3 (NLRP3) inflammasome/DAMP signalling after acute SCI in rats. Compared with ADMSCs only, the capabilities of PrPcOE‐ADMSCs were significantly enhanced in cellular viability, anti‐oxidative stress and migration against H2O2 and lipopolysaccharide damages. Similarly, PrPcOE‐ADMSCs significantly inhibited the inflammatory patterns of Raw264.7 cells. The SD rats (n = 32) were categorized into group 1 (Sham‐operated‐control), group 2 (SCI), group 3 (SCI + ADMSCs) and group 4 (SCI + PrPcOE‐ADMSCs). Compared with SCI group 2, both ADMSCs and PrPcOE‐ADMSCs significantly improved neurological functions. Additionally, the circulatory inflammatory cytokines levels (TNF‐α/IL‐6) and inflammatory cells (CD11b/c+/MPO+/Ly6G+) were highest in group 2, lowest in group 1, and significantly higher in group 3 than in group 4. By Day 3 after SCI induction, the protein expressions of inflammasome signalling (HGMB1/TLR4/MyD88/TRIF/c‐caspase8/FADD/p‐NF‐κB/NEK7/NRLP3/ASC/c‐caspase1/IL‐ß) and by Day 42 the protein expressions of DAMP‐inflammatory signalling (HGMB1/TLR‐4/MyD88/TRIF/TRAF6/p‐NF‐κB/TNF‐α/IL‐1ß) in spinal cord tissues displayed an identical pattern as the inflammatory patterns. In conclusion, PrPcOE‐ADMSCs significantly attenuated SCI in rodents that could be through suppressing the inflammatory signalling. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results